Welcome to a thought-provoking episode of our podcast series, where we dive into the ethical and practical challenges of CAR T-cell therapy with Professor Marie José Kersten from Amsterdam University Medical Centers.

In this episode, our host Dr Isabel Olivera engages in a deep dive with Professor Kersten on the intricacies of patient access to CAR T-cell therapy, the ethical considerations in patient selection, and the financial implications of this groundbreaking treatment.

Discover the rigorous process of patient eligibility assessment in the Netherlands, the national CAR-T tumorboard's role, and the ongoing efforts to make CAR T-cell therapy more accessible across different regions. Join us as we explore the potential of clinical trials in advancing treatment options, the quest for cost-effective manufacturing methods, and the critical importance of ethical decision-making in healthcare.

This conversation also offers valuable advice for hematologists and sheds light on the importance of multidisciplinary discussions in improving patient outcomes. Don't miss this insightful discussion that navigates the complexities of modern medicine and the future of lymphoma treatment.

Host: Dr Isabel Olivera Martinez

Guest: Prof Marie José Kersten

This is part of a series recorded at the joint EHA-EBMT 6th European CAR T-cell meeting in Valencia in February 2024, more podcasts will be available in the future. Stay tuned!

Interested in more content related to CART? We've got you covered. Check out free CART program on EHA Campus.

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: education@ehaweb.org

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe

Join us for a conversation with Jonathan Clark, a patient advocate who has been in remission for over five years after receiving CAR T-cell therapy for Mantle Cell Lymphoma.

Jonathan shares his journey from relapse to recovery, detailing the challenges and triumphs of this cutting-edge treatment from a patient’s perspective. With host Dr. Sarah de Vlieger, they discuss his motivation for sharing his story and the profound physical and psychological impacts of long-term remission.

Jonathan also talks about managing long-term side effects like immunodeficiencies and how apparently small changes can significantly improve quality of life. He emphasizes the importance of understanding the patient's perspective, advocating for quality of life improvements, and the need for personalized care that goes beyond medical statistics. Jonathan highlights the global disparities in accessing advanced treatments like CAR T-cell therapy and concludes with a call to prioritize quality of life in treatment decisions.

Host: Dr Sarah de Vlieger

Guest: Jonathan Clark

This episode is part of a series recorded at the joint EHA-EBMT 6th European CAR T-cell meeting in Valencia in February 2024.

Interested in more content related to CART? We've got you covered. Check out free CART program on EHA Campus.

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: education@ehaweb.org

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe

Join us for a captivating interview with our guest Professor Michael Hudecek from the Universitätsklinikum Würzburg in Germany as he offers his insights on the latest advancements in CAR T-cell therapy and gene-engineered immune cell therapies.

Together with our host Dr. Isabel Olivera Martinez, they discuss the mounting real-world data on CAR T-cell treatments and how AI is helping analyze this data to design new strategies and extend CAR-T to new indications.

Discover the strides being made to predict and manage treatment-related toxicities and to make CAR T-cell therapy more accessible and affordable, including potential off-the-shelf treatments and automated manufacturing techniques.

Learn about the role of gene editing and the challenges of creating universally compatible immune cell products. Finally, gain insights from the 2024 CAR T-cell meeting, where groundbreaking clinical updates and new applications of CAR-T to autoimmune and cardiovascular diseases were showcased.

Host: Dr Isabel Olivera Martinez

Guest: Prof Michael Hudecek

This is part of a series recorded at the joint EHA-EBMT 6th European CAR T-cell meeting in Valencia in February 2024, more podcasts will be available in the future. Stay tuned!

Interested in more content related to CART? We've got you covered. Check out free CART program on EHA Campus.

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: education@ehaweb.org

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe

Join us on this podcast episode featuring Prof. Maria Teresa Voso (Tor Vergata University of Rome, Italy) as she offers her insights on the latest advancements in precision medicine for diagnosing and treating myelodysplastic syndromes (MDS).

In this interview with our EHA host, Dr. Isabel Olivera Martinez, Prof. Voso begins by explaining how the use of NGS myeloid panels in identifying individual myeloid mutations enhances the diagnostic accuracy of MDS. Our guest then discusses the novelties in the 2022 WHO and ICC MDS classifications and the significance of germline predisposition. Furthermore, she explores the emerging targeted therapies for MDS, including lenalidomide, luspatercept, and imetelstat.

This episode offers a comprehensive overview of the evolving landscape of MDS diagnosis and management, highlighting the importance of personalized approaches in improving patient outcomes.

Host: Isabel Olivera-Martinez, PhD

Guest: Prof Maria Teresa Voso

This is the ninth episode in a series of podcasts covering precision medicine across various disorders; more podcasts will be available in the future. Stay tuned!

Interested in more content related to MDS? We've got you covered. Check out podcasts, clinical cases, courses, and more on EHA Campus.

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: education@ehaweb.org

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe

Join us for a stimulating conversation with our guest Dr. Eleni Gavriilaki, from G. Papanicolaou Hospital and Aristotle University of Thessaloniki in Greece, as she shares her insights on one of her passions: diversity, equity, and inclusion (DEI) in hematology. Together with our host Dr. Sarah de Vlieger, they discuss the current challenges of DEI in the field and how organizations like EHA are addressing these issues.

They examine the importance of representation across gender, age groups and geographical location and how this impacts both clinical and research practices. Dr. Gavriilaki highlights ongoing initiatives to promote DEI, such as inclusive speaker selection, recruiting hematologists from diversity groups to leading roles, creating equitable grant opportunities. She further emphasizes the need for conscious efforts to provide opportunities to hematologists from underrepresented countries.

This conversation concludes with a call to action for hematologists who feel underrepresented to seize the current momentum and make their voices heard.

If you feel inspired to learn more about EHA’s DEI Initiatives, please feel free to check out the EHA Taskforce on Diversity, Equity, and Inclusion or reach out to membership@ehaweb.org.

Host: Sarah de Vlieger, EHA Head of Education

Guest: Dr. Eleni Gavriilaki

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: education@ehaweb.org

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe

Join us for a captivating interview with our guest Professor Carl June, Director of the Centre for Cellular Immunotherapies at the University of Pennsylvania, USA, as he discusses the current directions in CAR T-cell therapy.

Together with our host Dr. Sarah de Vlieger, they examine the latest results on both pediatric and adult patients with over ten years of follow up. They cover ongoing trials aimed at drastically reducing the vein-to-vein time for autologous CAR T-cells, as well as trends toward academic manufacturing and the full automation of production processes.

Finally, Prof. June provides insight into USA FDA’s warning about secondary malignancies in CAR T-cell-treated patients issued in November 2023.

Host: Sarah de Vlieger, EHA Head of Education

Guest: Prof Carl June

This is the first of a series of podcasts recorded at the 6th European CAR T-cell meeting in Valencia in February 2024, more podcasts will be available in the future. Stay tuned!

Interested in more content related to CART? We've got you covered. Check out free CART program on EHA Campus.

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: education@ehaweb.org

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe

Join us for a discussion with Prof Paolo Ghia, MD, PhD, from Università Vita Salute San Raffaele, Milan (Italy), as he explores how precision medicine is transforming CLL treatment.

In this episode, discover how precision medicine is used daily in CLL to decide the best management and treatment for patients. Listen to Prof Ghia explain how CLL management is moving from traditional chemotherapy to targeted therapies based on specific genetic markers, like immunoglobulin mutational status or P53 aberrations, which help guide treatment decisions.

Explore the array of targeted therapies available for CLL, including BTK inhibitors and BCL-2 inhibitors, and understand how they target critical pathways in CLL pathogenesis. Gain insights from Prof Ghia on the complexities of selecting the right therapy for each patient based on genetic profile, disease risk, and individual preferences.

Through the discussion, recognise the challenges in CLL management, such as relapse scenarios and emerging therapies, and learn the research strategies being explored for potential cures in CLL

This is a series of podcasts covering precision medicine across several disorders, more podcasts will be available in the future. Stay tuned!

Host: Isabel Olivera-Martinez, PhD

Guest: Prof Lucia de Franceschi

This is the eighth episode in a series of podcasts covering precision medicine across various disorders; more podcasts will be available in the future. Stay tuned!

Interested in more content related to CLL? We've got you covered. Check out podcasts, clinical cases, courses, and more on EHA Campus.

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: education@ehaweb.org

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe

Join us on this podcast episode featuring Prof Lucia de Franceschi (Department of Medicine, University of Verona, Italy) as she discusses the latest advances on the use of Pyruvate kinase activators in the treatment of rare hematological diseases.

Learn about the crucial role of Pyruvate kinase (PK) in erythrocyte metabolism and how pyruvate kinase activators are emerging as a new therapeutic option for chronic hemolytic anemias that had previously no other treatment than transfusion or iron chelation.

Discover how two oral pyruvate kinase activators, Mitapivat and Etavopivat, can help improve ineffective erythropoiesis and survival of red cells and therefore are being tested as a new therapeutic scenario for non-transfusion dependent thalassemia patients and sickle cell disease patients.

Discover how PK activators are able to reprogram red cells to a more normal metabolite context, which can have a beneficial effect in a wide range of rare diseases all characterized by an abnormal metabolite profile, which represents the ideal breakthrough in the management of rare diseases, as one drug has the ability to treat multiple disorders.

This is a series of podcasts covering precision medicine across several disorders, more podcasts will be available in the future. Stay tuned!

Host: Isabel Olivera-Martinez, PhD

Guest: Prof Lucia de Franceschi

This is the seventh episode in a series of podcasts covering precision medicine across various disorders; more podcasts will be available in the future. Stay tuned!

Matte, Alessandro, Enrica Federti, and Lucia De Franceschi. 2023. ‘Erythrocyte Pyruvate Kinase Activation in Red Cell Disorders’. Current Opinion in Hematology 30 (3): 93. https://doi.org/10.1097/MOH.0000000000000758.

Interested in more content related to Thalassemia? We've got you covered. Check out podcasts, clinical cases, courses, and more on EHA Campus.

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: education@ehaweb.org

Subscribe to receive the EHA Educational Updates via